Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2003 April;55(2) > Minerva Ginecologica 2003 April;55(2):107-16

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  


Minerva Ginecologica 2003 April;55(2):107-16

language: English

Hormone replacement therapy. Current controversies

Burkman R. T.


PDF  


Hormone replacement therapy has had a controversial history since its introduction for medical use several decades ago. Current evidence indicates that users of hormone replacement therapy have an increased risk of venous thromboembolism, stroke, and coronary heart disease compared to non-users. Among users, the risk of breast cancer is modestly increased. This effect becomes apparent after 4 to 5 years use and primarily with use of combination estrogen plus progestin products. The risk of colorectal cancer is decreased with use of hormone replacement therapy. In addition, the risk of osteopenia and osteoporosis is decreased as is the risk of osteoporotic fracture.

top of page

Publication History

Cite this article as

Corresponding author e-mail